Shots:

• The P-III ETHOS study involves assessing of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) vs dual therapies [Bevespi Aerosphere (glycopyrronium/formoterol fumarate) and PT009 (budesonide/formoterol fumarate)] with mod. to sev. COPD and a history of exacerbation(s) in the previous year
• A post-hoc analysis of the P-III ETHOS trial demonstrated a consistent benefit of Breztri Aerosphere in reducing the rate of mod. or sev. COPD exacerbations across all seasons
• AstraZeneca will present 60 abstracts from an inhaled and biologics portfolio and pipeline at the ERS Congress. Breztri Aerosphere is an approved therapy in Japan and China for patients with COPD and is under regulatory review in the EU

­ Ref: AstraZeneca | Image: Reuters